Market Research Blog

The latest revised edition on ‘cancer tissue diagnostics’ market study by Future Market Insights (FMI) provides a holistic overview of the global industry along with thorough analysis of the demand-supply patterns, and growth & restraining factors during the forecast period of 2021 to 2031. According to the report, the cancer tissue diagnostics industry will expand at close to 8.5% CAGR, while North America, Western Europe, Asia Pacific, and Latin America will remain hotspots for stakeholders in this industry. As per the report, North America will have the highest market share, more than 40%, through 2031.

Key Takeaways from Study

• Rapid traction of immunohistochemistry (IHC) test to propel the demand growth
• The United States to maintain its lead in the world’s biggest cancer tissue diagnostics industry North America
• Germany to remain the major contributor to Western Europe cancer tissue diagnostics industry
• China and India remain lucrative in the APEJ (Asia Pacific Excluding Japan) cancer tissue diagnostics industry
• The United States, Japan, France, Italy, South Korea, and a few other countries to exhibit significant growth through 2031

“Growing inclination towards biomarker tests is anticipated to bolster the demand for cancer tissue diagnostic solutions substantially. As per the data revealed by the Organization for Economic Co-Operation and Development (OECD), the global biomarkers industry for companion diagnostics was worth US$ 8.4 Billion in 2016. As this value is forecast to rise further, the cancer tissue diagnostic solution providers are subject to higher revenue in the coming years,” says an FMI analyst.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-4191

How Rise in Cases of Cancer is Spearheading the Growth of Cancer Tissue Diagnostic Equipment Manufacturers?According to the report on cancer published by the World Health Organization (WHO) on 3^rd March, 2021, approximately 70% of deaths from cancer occur in low and middle-income countries, while cancer is the second leading cause of death globally and is responsible for approximately 10 million deaths per year. While this indicates the fatality and risks associated with cancer, it also signifies the importance of early diagnosis of cancer, which is resulting in growing adoption of timely diagnosis for various cancers such as lungs, breast, colon, and liver, to name a few.

The recent report by WHO states that late-stage presentation and lack of access to diagnosis and treatment are what make it more fatal for patients, while comprehensive treatment is reportedly available in more than 90% of high-income countries. Such reports are spreading awareness among people, which in turn is favoring the suppliers of cancer tissue diagnostics equipment.

Who is Winning in this Space?With the competition getting stricter, key players in the global cancer tissue diagnostics industry are embracing strategic ways to launch more effective products to target broader application areas. For instance,

• Abbott Laboratories launched its new products such as Vysis ALK Break Apart FISH Probe Kit, and others in the last 5 years
• Bio Rad Laboratories Inc. launched its new Liquicheck™ Tumor Marker Control equipped with 3 levels and 17 cancer antigens and popular tumor markers a couple of years back

More Valuable InsightsIn its latest report, FMI offers an unbiased analysis of the cancer tissue diagnostics market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of test type (immunohistochemical (IHC) test (breast cancer, stomach (gastric) cancer, colorectal cancer, prostate cancer, and others) and in situ hybridization (ISH) test (breast cancer, non-small cell lung cancer (NSCLC), bladder cancer, and others)) across seven major regions of the world (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-4191

Cancer Tissue Diagnostics Market – Segmentation by CategoryTest Type

• Immunohistochemical (IHC) Test
  • Breast Cancer
  • Stomach (Gastric) Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others
• In Situ Hybridization (ISH) Test
  • Breast cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Bladder Cancer
  • Others

Region

• North America
• Latin America
• Europe
• Middle East and Africa (MEA)
• East Asia
• South Asia
• Oceania

Rise in geriatric population and preference for less time-consuming treatment are the key factors fuelling the Gamma Knife market in North America. Increase in the prevalence of cancer, coupled with shift towards painless and non-invasive surgeries are other key drivers of the market.

Rise in per capita healthcare expenditure is also fuelling the Gamma Knife market in North America. For example, 17.7% of America’s GDP was spent on healthcare in 2011. Increase in funding for R&D on non-invasive treatment is also providing an impetus to the Gamma Knife market in North America.

According to Cancer.org, in the US, nearly 1,658,370 new cancer cases are expected to be diagnosed in 2015. Owing to these new diagnoses, the demand for non-invasive treatment options is expected to witness a surge.

In terms of compound annual growth rate (CAGR) and market value, FMI expects Asia Pacific Excluding Japan (APEJ) to emerge as the most lucrative market by the end of forecast period.

Currently valued at US$ 43.9 Mn, the Asia Pacific Excluding Japan (APEJ) Gamma Knife market is projected to expand at over 10% CAGR through 2025, reaching a valuation of US$ 131.5 Mn. APEJ is expected to account for nearly 30% of the market value share of the global Gamma Knife market by 2025.

The same factors that are driving the North America Gamma Knife market are fuelling the market in APEJ as well. However, the funding for research and development is expected to be comparatively lower than that in North America.

The leading companies operating in the Gamma Knife market are Elekta, Varian Medical Systems, and Huiheng Medical.

Gamma Knife tools account for nearly 40% of total revenues of Elekta. The company has a strong presence in North America and Europe. The company has strategic partnerships with prominent institutes, such as Swedish Cancer Institute and Ottawa Hospital.

FMI’s research on the Gamma Knife market revealed that approximately 950 employees at Elekta are involved in research and development activities. The company aims to exploit market opportunities and focus on radiotherapy market. The company’s capacity to drive the business further from the existing installed base becomes critical as it is subject to stringent market expectations.

North America is the most lucrative market for Varian Medical System, with the region accounting for nearly 46% of the total revenues. The company has a strong presence globally in terms of brand recognition and technology.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-589

A key opportunity for Varian Medical System is to expand in invasive surgery equipment by leveraging established brands. However, lack in safety measures for patients and staff from high radiations.

The company is focusing on R&D activities for high-quality and software which require trained professional for usage and safety. These activities involve increasing interconnectivity of products for a seamless operation.

Gamma Knife Market – Key SegmentBy Disease Indication:

• Brain Metastasis
• Cancer
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Others

By Anatomy:

• Head
• Neck
• Other Body Parts

By Geography:

• North America
• Europe
• APAC
• Latin America
• Middle East and Africa

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-589

Continuous renal replacement therapy is conducted for blood purification in patients suffering from acute kidney injury who unable to withstand rapid fluid and electrolyte exchange of conventional hemodialysis. Continuous renal replacement therapy involves the removal of blood from the arterial lumen catheter through the peristaltic movement and pushing it through a hemofilter before getting pumped into a patient via a venous lumen of catheter. Rising incidence of acute kidney injuries, multiple organ failure and other renal injuries had increased the demand for dialysis sessions.

Numerous advantages of continuous renal replacement therapy over the conventional dialysis procedure is a primary factor driving the adoption of continuous renal replacement therapy. Conventional dialysis systems are operated manually and all associated tasks are solely controlled by the user or caregiver. However, technological advancements in currently available continuous renal replacement systems allows the automatic management of disease parameters. Hence, most of the problems are being directly handled by automated digital machines, which is not possible in case of conventional systems, thus reducing the labour cost.

To expand their commercial footprint across the globe, several manufacturers of continuous renal replacement therapy are focusing on introducing new technologies and upgrading their existing products along with simultaneous focus on strategic alliances for the sale and promotion of their products. For instance, in 2015, Fresenius Medical Care AG & Co. KGaA launched multi Filtrate PRO, a therapy system for continuous renal replacement therapy for the treatment of acute kidney failure in critically ill patients at intensive care units. Innovations in extracorporeal technologies will play a critical role in the long-term sustainability of continuous renal replacement therapy devices. The advent of continuous renal replacement therapy devices will eventually attract a new patient base. For instance, in September 2017, Baxter International Inc. launched 3-In-1 oXiris Set for sepsis management protocols & continuous renal replacement therapy, which was previously indicated only for continuous renal replacement therapy. The commercialisation of such multimodal devices is expected to enhance the ROI for hospitals. The introduction of novel autonomous CRRT devices will marginally reduce physician intervention and the cost of treatments in intensive care units. The intuitive platform with touch screen and step-by-step automated instructions promotes ease of use during procedures.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1211

Companies are investing in future growth by expanding their healthcare services businesses through acquisitions as well as the purchase of expertise and relevant technologies in the area of research and development. In 2016, Fresenius Medical Care spent US$1.3 Bn on capital expenditures, acquisitions and the purchase of intangible assets minus income from divestments. The majority of capital expenditures were used for equipping existing & new clinics, preserving & expanding production capacity, primarily in North America, Germany, Asia Pacific and France, as well as for dialysis machines made available to customers and for care coordination.

FMI segmented the global continuous renal replacement therapy market into product type, end user & regions. In terms of revenue, the consumables segment is expected to hold a substantial market share over the forecast period. The segment is expected to exhibit a significant CAGR of 8.5% over the forecast period.

FMI’s report covers some of the key companies operating in the continuous renal replacement therapy market, which include Fresenius Medical Care AG & Co. KGaA; Baxter International Inc.; B. Braun Melsungen AG; Medica SpA, Nikkiso Co., Ltd.; Nipro corp.; Toray Medical Co., Ltd.; NxStage Medical, Inc.; Asahi Kasei Corp. and Medtronic plc.

SegmentationThe report offers a comprehensive taxonomy of the continuous renal replacement therapy market based on product type, end user and region. Continuous renal replacement therapy is sold in two types: systems and consumables. The consumables segment covers various types of hemofilter sets, solutions and other accessories.

Increased healthcare spending across emerging economies is expected to encourage the establishment of new multi-specialties in dialysis centres and hospitals, which is, in turn, expected to promote the demand for CRRT. The continuous renal replacement therapy market has been analysed across various regions, which include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and MEA.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1211

Single-dose radiotherapy substitutes the requirement for extra hospital visits, with benefits for patient safety and well-being. Single-dose radiotherapy is delivered during or soon after surgery for breast cancer and is considered a viable alternative to conventional external beam radiotherapy.

Increasing technological advancements in radiotherapy procedure for the treatment of breast cancer and prostate cancer have led to the surging adoption of single-dose radiotherapies in clinical practice associated with improved outcomes. Single-dose radiotherapy is recognized as an extremely cost-effective treatment compared with other cancer treatments.

Increasing investments in the market, increasing number of research and development projects, and favorable regulatory policies are some factors enabling growth in the single dose radiotherapy services market. For example various government organizations such as American Cancer Society is investing in research and development programs for development of single dose radiotherapy. Recently the American cancer society have funded almost 162 research programs with around $67 million to encourage breast cancer research activities.

The COVID-19 pandemic has changed the national healthcare significances and expenditure however this is considered to be a short-term impact on the single-dose radiotherapy services market. The single-dose radiotherapy services market is expected to experience short-term negative growth owing to a sharp reduction in the number of single-dose radiotherapy services adoption rate in developed and emerging countries.

As a result of the continuing spread of COVID-19, various service providers are focusing on a novel approach to the treat pneumonia associated with COVID-19 using a single low dose of external beam radiation therapy which is known as Single Dose Radiation Therapy (SDRT). Previously various studies are reported regarding use of single small fraction of radiation to treat viral and bacterial pneumonia. Thus, scientists are believing that one small dose of radiotherapy can be effective for covid-19 treatment. This is providing an opportunity for single dose radiotherapy market to grow.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13033

Key Takeaways from Single-Dose Radiotherapy Services Market Study

• Despite restricted growth amid COVID-19, the demand for single dose radiotherapy is expected to rise at nearly 5% in 2021
• As a result of increasing incidence of breast cancer, the U.S. will account for over 90% sales in North America
• Increasing focus on early diagnosis will enable the U.K. register 2.4% Y-o-Y growth in 2021
• Germany and France are expected to exhibit increasing demand to tackle concerns pertaining to rising incidence of cancer
• Increasing focus on research and development will drive growth in Japan and South Korea

 “Rising prevalence along with increasing awareness regarding breast and prostate cancer and the importance of early diagnosis, besides favorable reimbursement will offer lucrative growth opportunities for service providers in the long term,” says the FMI Analyst

Increase in Funding For Research Activities Offers Growth OpportunitiesLeading service providers in the single dose radiotherapy services market are strengthening their market position through collaboration with various government organization. Governments in various developed and developing countries are actively taking initiatives to encourage various research activities for the development of single-dose radiotherapy. For instance, In Brazil, government is taking initiative to create awareness regarding cancer treatment and research programs.

Pink October campaigns are arranged in Brazil by government, whose aim is to share facts about breast cancer, promoting awareness, providing countless access to diagnostic and therapeutic services, and funding to reduced mortality. One more example is the Blue November campaign, which works analogously to Pink October, however emphasize on prostate cancer.

Who is Winning?The global market is set to expand in the forecast period, due to the rising prevalence of breast cancer and prostate cancer globally and the adoption of single-dose radiotherapy. Leading organizations within the market are set to focus on research and development to offer early and precise diagnosis of the ailment, besides offering effective patient care.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13033

Want more insights?Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global single-dose radiotherapy services market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the single-dose radiotherapy services market on basis of the main indication in detail, cover every aspect of the market such as (breast cancer and prostate cancer), therapy (External Beam Radiotherapy and Internal Beam Radiotherapy), and service provider (Hospitals, Radiotherapy Centers and Specialized cancer institute) across seven major regions.

Single Dose Radiotherapy Services Market by CategoryIndication

• Breast Cancer
• Prostate Cancer

Therapy

• External Beam Radiotherapy
• Internal Beam Radiotherapy

Service Provider

• Hospitals
• Radiotherapy Centers
• Specialized Cancer Institutes

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• The Middle East and Africa (MEA)
• Oceania

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/13033

Ocular drug delivery systems are designed for dispensing drug, biologic, biopharmaceutical, and botanical therapeutics for treating macular degeneration, glaucoma, presbyopia, allergy, anti-viral, dry eye, anti-infective and anti-inflammatory indications.

To overcome the ocular drug delivery barriers and improve ocular bioavailability, various conventional and novel drug delivery systems have been developed such as  ointments, emulsion, suspensions, aqueous gels, Nano micelles, liposomes, , and in situ thermosensitive gels for the earlier mention ocular diseases.

Glaucoma is the second-leading cause of blindness worldwide, accounting for up to 8% of total blindness. In India, glaucoma is the leading cause of irreversible blindness with at least 12 million people affected and nearly 1.2 million people blind from the disease. More than 90 percent of glaucoma cases remain undiagnosed in the community.

Thus the high incidence of ophthalmic diseases, resulting in the rise significant patient population, is driving the global ocular drug delivery systems market.

Ocular drug has to pass the water-fat-water membranous structure of cornea and this changing environment presents a significant barrier. That is why, for almost four decades, researchers have been involved in developing intraocular sustained-release drug delivery platforms.

Owing to the rigorous research studies, approvals for new ocular drug delivery techniques are currently recorded globally. This has helped the market to gain momentum over the last few years.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-6027

Key Takeaways from Ocular Drug Delivery System Market Study

• Increasing focus on pharmaceutical innovation and research on drug delivery technologies is driving a transition towards particulate drug delivery systems, which will account for over 68% of the market in 2021.
• Ophthalmic solution for ocular drug delivery system is expected to account for 60% the global market share by 2031.
• Among distribution channels, hospital pharmacies accounted for 40% of the market share in 2031. Soaring influx of patients for treatment and availability of intensive care support have propelled the demand in the sehment.
• North America holds the maximum share, owing to the presence of Tier1 players, high per-capita healthcare expenditure, and favorable reimbursement policies in the region.
• The U.S. holds a more than 44% share in the global ocular drug delivery systems market.
• The U.K. and Germany are leading markets in Europe, accounting for more than 41% of the Europe market in 2021.
• South Korea is the fastest growing market in East Asia, exhibiting 10.3% CAGR through 2031.

“Increasing prevalence of eye infections, innovation in drug delivery technologies, and rising clinical trials are creating lucrative growth opportunities for ocular drug delivery system sales,” says the Future Market Insight analyst.

Increase in Funding for Research Activities Offers Growth OpportunitiesLeading manufacturers in the ocular drug delivery system market are strengthening their market position through collaboration with various other organizations. Governments in developed and developing countries are actively taking initiatives to encourage research pharmaceutical products.

For instance, In April, 2017, Santen Pharmaceuticals announced a strategic investment in Regenerative Patch Technologies LLC, a U.S. based company engaged in development of ophthalmic therapies.

Pharmaceutical giants are expected to benefit from the globalization of labor forces, that is, employment of skilled local labor at cheaper rates to derive larger cost savings. Furthermore, this will create room for research and development (R&D) investments.

As per data from EFPIA and PhRMA, annual pharmaceutical (R&D) expenditures increased at 2.5% p.a. in Europe as compared to 3.3% p.a. in the U.S. over the latest measurable period 2016-2020. This will also create opportunities for the expansion of the market.

Who is Winning?The global market is set to expand due to the rising prevalence of eye infections. Leading players within this space are expected to focus on research and development to offer an early and precise diagnosis of ailment, besides offering effective patient care.

Some of the leading players in the ocular drug delivery system market include but are not limited to Allergan Plc., Graybug Vision Inc., Ocular Therapeutix, Inc., Alimera Sciences, pSivida, Santen Pharmaceutical Co., Ltd, Taiwan Liposome Company Ltd., Envisia Therapeutics, Eyegate Pharma, Valeant Pharmaceuticals International, Inc, Vision Ophthalmology Group GmbH, Clearside Biomedical, URSAPHARM Arzneimittel GmbH.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-6027

Want More Insights?Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global ocular drug delivery systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the ocular drug delivery systems treatment on basis of the key indication in detail, cover every aspect of the market such as technology, dosage form, distribution channel across seven major regions.